Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | PI4KA | P42356 | 2/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | GAPDH | P04406 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13238881 | 0.99 | EGFR (0.41) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL2045673 | 0.99 | EGFR (0.41) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL1140703 | 0.99 | EGFR (0.41) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL2950100 | 0.97 | EGFR (0.40) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL1980312 | 0.84 | ADORA3 (0.57) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL112551 | 0.84 | ADORA3 (0.57) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL13238880 | 0.84 | POLB (0.43) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL7153500 | 0.84 | ADORA3 (0.57) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL15759284 | 0.82 | LMNA (0.38) | EGFRERBB2ADORA3PI4KAPI4K2B | |
| SCHEMBL2955999 | 0.80 | BCHE (0.42) | ADORA3ADORA2BBCHEALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750153-B2 | Process for the preparation of didanosine using novel intermediates | HETERO DRUGS LIMITED (IN) | 2010-07-06 | — | — | US | claimed |
| US-20080293938-A1 | Novel Process for the Preparation of Didanosine Using Novel Intermediates | HETERO DRUGS LIMITED (IN) | 2008-11-27 | — | — | US | claimed |
| US-7750153-B2 | Process for the preparation of didanosine using novel intermediates | HETERO DRUGS LIMITED (IN) | 2010-07-06 | — | — | US | disclosed |
| US-7750153-B2 | Process for the preparation of didanosine using novel intermediates | HETERO DRUGS LIMITED (IN) | 2010-07-06 | — | — | US | disclosed |
| US-20080293938-A1 | Novel Process for the Preparation of Didanosine Using Novel Intermediates | HETERO DRUGS LIMITED (IN) | 2008-11-27 | — | — | US | disclosed |
| US-20080293938-A1 | Novel Process for the Preparation of Didanosine Using Novel Intermediates | HETERO DRUGS LIMITED (IN) | 2008-11-27 | — | — | US | disclosed |
| EP-1910393-A2 | A NOVEL PROCESS FOR THE PREPARATION OF DIDANOSINE USING NOVEL INTERMEDIATES | Hetero Drugs Limited (IN) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910393-A2 | A NOVEL PROCESS FOR THE PREPARATION OF DIDANOSINE USING NOVEL INTERMEDIATES | Hetero Drugs Limited (IN) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007004230-A3 | A NOVEL PROCESS FOR THE PREPARATION OF DIDANOSINE USING NOVEL INTERMEDIATES | HETERO DRUGS LTD (IN) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007004230-A2 | A NOVEL PROCESS FOR THE PREPARATION OF DIDANOSINE USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007004230-A2 | A NOVEL PROCESS FOR THE PREPARATION OF DIDANOSINE USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293938-A1 | Novel Process for the Preparation of Didanosine Using Novel Intermediates | ITPA, NUDT1, IMPDH2 | EGFR 3899/4885ERBB2 4401/4885ADORA3 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.